PCSK9 GENETIC VARIANTS IN PATIENTS WITH CORONARY ARTERY DISEASE - A PILOT STUDY

被引：0
|
作者：
Ashavaid, T. F. [1 ,2 ]
Bane, A. [1 ,3 ]
Ponde, C. K. [1 ,4 ]
Rajani, R. M. [1 ,4 ]
Pillai, S. [1 ,4 ]
机构：
[1] PD Hinduja Hosp, Bombay, Maharashtra, India
[2] MRC, Dept Lab Med, Bombay, Maharashtra, India
[3] MRC, Res Labs, Bombay, Maharashtra, India
[4] MRC, Dept Cardiol, Bombay, Maharashtra, India
来源：
ATHEROSCLEROSIS | 2018年 / 275卷
关键词：
D O I：
10.1016/j.atherosclerosis.2018.06.708
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P5.3.421
引用
收藏
页码：E224 / E225
页数：2
相关论文
共 50 条
  • [1] GENETIC VARIANTS OF PCSK9 GENE IN CORONARY ARTERY DISEASE AMONG SOUTH INDIAN PATIENTS
    Ganesan, M.
    [J]. ATHEROSCLEROSIS, 2016, 252 : E47 - E47
  • [2] THE STUDY OF PCSK9 GENE VARIANTS IN CORONARY HEART DISEASE
    Akadam, Aysegul Basak
    Yilmaz-Aydogan, Hulya
    Isbir, Turgay
    Tekeli, Atike
    Isbir, Selim
    [J]. IUBMB LIFE, 2009, 61 (03) : 329 - 329
  • [3] NO ASSOCIATION BETWEEN CHANGES IN LIPID PARAMETERS AND TOTAL PCSK9 IN CORONARY ARTERY DISEASE PATIENTS TREATED WITH PCSK9 INHIBITORS
    Ugovsek, S.
    Likozar, A. Rehberger
    Sebestjen, M.
    [J]. ATHEROSCLEROSIS, 2023, 379 : S173 - S173
  • [4] Effect of PCSK9 inhibition on platelet reactivity in coronary artery disease patients
    Galli, Lukas
    Ondracek, Anna
    Seidl, Veronika
    Hofbauer, Thomas
    Zedan, Yasmin
    Schrutka, Lore
    Krychtiuk, Konstantin
    Lang, Irene M.
    Speidl, Walter
    Distelmaier, Klaus
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2019, 131 : 372 - 373
  • [5] Regression of Coronary Atherosclerosis With the PCSK9 Inhibitor Evolocumab in Patients With Coronary Artery Disease and Diabetes
    King, Peta
    Puri, Rishi
    Koenig, Wolgang
    Brennan, Danielle M.
    Somaratne, Ransi
    Kassahun, Helina
    Wasserman, Scott M.
    Nissen, Steven E.
    Nicholls, Stephen J.
    [J]. CIRCULATION, 2017, 136
  • [6] Joint Genetic Inhibition of PCSK9 and CETP and the Association With Coronary Artery Disease A Factorial Mendelian Randomization Study
    Cupido, Arjen J.
    Reeskamp, Laurens F.
    Hingorani, Aroon D.
    Finan, Chris
    Asselbergs, Folkert W.
    Hovingh, G. Kees
    Schmidt, Amand F.
    [J]. JAMA CARDIOLOGY, 2022, 7 (09) : 955 - 964
  • [7] Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease
    Zhang, Yan
    Zhu, Cheng-Gang
    Xu, Rui-Xia
    Li, Sha
    Guo, Yuan-Lin
    Sun, Jing
    Li, Jian-Jun
    [J]. JOURNAL OF CLINICAL LIPIDOLOGY, 2014, 8 (05) : 494 - 500
  • [8] PROGNOSTIC VALUE OF PCSK9 AND LP(A) IN STABLE CORONARY ARTERY DISEASE
    Acena, Alvaro
    Alvarez de Toledo, Cristina
    Maria Pello, Ana
    Tarin, Nieves
    Cristobal, Carmen
    Huelmos, Ana
    Gutierrez Landaluce, Carlos
    Lopez Castillo, Marta
    Lorenzo, Oscar
    Martin Mariscal, Maria Luisa
    Martinez Milla, Juan
    Gonzalez Lorenzo, Oscar
    Hernandez Gonzalez, Ignacio
    Tunon Fernandez, Jose
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 100 - 100
  • [9] Thyroid function and PCSK9 in euthyroid subjects with coronary artery disease
    Li, Sha
    Xu, Rui-Xia
    Guo, Yuan-Lin
    Zhang, Yan
    Zhu, Cheng-Gang
    Sun, Jing
    Li, Jian-Jun
    [J]. CLINICAL LIPIDOLOGY, 2015, 10 (03) : 235 - 242
  • [10] Role of PCSK9 Inhibitors in Acute Coronary Syndromes - A Pilot Study
    Abdelnabi, Mahmoud
    Benjanuwattra, Juthipong
    Saleh, Yehia
    Del Rio-Pertuz, Gaspar
    Leelaviwat, Natnicha
    Almaghraby, Abdallah
    [J]. CIRCULATION, 2022, 146
12345